Australian Quarantine & Inspection Service approves permit for NKO(R)
LAVAL, QC, Dec. 5 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has
received notification from the Therapeutic Goods Administration (TGA) in
Australia that Neptune Krill Oil (NKO(R)) has obtained approval as a
complementary medicine allowing immediate commercialization in Australia hence
New Zealand, which automatically allows TGA approved products.
The Department of Health and Aging of the TGA has accepted and
registered, in the Australian Register of Therapeutic Goods, Neptune Krill Oil
under the Australian Approved Biological Name "Euphausia superba oil". In
addition, the Australian Quarantine and Inspection Service has granted a
permit to import quarantine material of NKO(R).
"In Australia and New Zealand complementary medicines are classified as a
subset of over-the-counter (OTC) pharmaceuticals," stated Dr. Tina Sampalis,
Chief Scientific Officer of Neptune. "Considering the very tight regulatory
control by the TGA, obtaining complementary medicine approval and the
quarantine permit constitute a major breakthrough for Neptune in Australia and
New Zealand," she added.
"Physician and other healthcare practitioner recommendations have always
had a positive impact on our sales. Bearing in mind that 50% of complementary
medicines in Australia are sold through medical recommendations and in
pharmacies(1), we are seeking a strategic alliance with a major local partner
in order to commercialize NKO(R) in these targeted markets. In order to
support penetration in this new market, Neptune expects to be actively
participating in the near future with such a partner in a series of medical
conventions, seminars and media conferences to introduce the scientific data,
clinical research and health benefits of NKO(R) to physicians and other
healthcare practitioners as well as the end consumer," added Dr. Sampalis.
1. Source: Australian Self-Medication Industry (ASMI)
About Neptune Technologies & Bioressources Inc.
Neptune develops proprietary health ingredients from underexploited
marine biomasses, such as krill, with its patented extraction process (Neptune
OceanExtract(TM)). Using its proprietary process, the Company is strategically
positioning itself in the health and wellness market.
Natural biomass extraction is now playing an important role in developing
nutrigenomics, the next wave in nutritional research. Through strategic
alliances and partnerships, as well as through clinical studies, the Company
continues to demonstrate the beneficial effects of these products. The Company
develops and markets new formulas and new products for specific applications
in high growth markets such as the nutraceutical, cosmeceutical,
biopharmaceutical and nutrigenomics markets.
Neptune continues to actively pursue its strategic development plan to
form partnerships/strategic alliances with worldwide leaders in the
nutraceutical and pharmaceutical industries. Neptune has recently signed
agreements with Nestlé and Yoplait, worldwide leading food manufacturers,
paving its entrance into the global functional food market. According to its
business strategy, negotiations are ongoing with pharmaceutical companies with
the objective of entering the pharmaceutical market by licensing rights.
NASDAQ and TSX venture exchange does not accept responsibility for the
adequacy or accuracy of this press release.
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of the Company to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the Securities and Exchange
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
email@example.com, www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.